TY - JOUR AU - Sane, David C; Stump, David C; Topol, Eric J; Sigmon, Kristina N; Kereiakes, Dean J; George, Barry S; Mantell, Susan J; Macy, Elizabeth; Collen, Désiré; Califf, Robert M TI - Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction SN - 0340-6245 SN - 2567-689X PY - 1991 JO - Thromb Haemost JF - Thrombosis and Haemostasis LA - EN VL - 65 IS - 03 SP - 275 EP - 279 DA - 2018/07/02 AB - Baseline plasminogen activator inhibitor (PAI) levels were examined for their influence on the responses to thrombolysis with recombinant tissue plasminogen activator (rt-PA) administered for acute myocardial infarction during the Thrombolysis and Myocardial Infarction (TAMI)-I study. Baseline PAI activity was 19 ± 21 IU/ml (normal <5 IU/ml) and baseline PAI-1 antigen 54 ± 53 ng/ml (normal 27 ± 16 ng/ml), confirming previous findings of elevated PAI levels during acute myocardial infarction. Among clinical outcomes, lower PAI-1 antigen levels correlated weakly with greater patency at the 90 min angiogram. Thus, high baseline plasma PAI-1 levels may be detrimental to reperfusion with t-PA. There was no correlation with other major in-hospital clinical outcomes including reocclusion at the 7-10 day angiogram, survival to discharge, or bleeding. During the follow up period of 2.0 ± 0.4 years, no relationship between baseline PAI levels and post-discharge reinfarction was observed. PB - Schattauer GmbH DO - 10.1055/s-0038-1648134 UR - http://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0038-1648134 ER -